首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors
【2h】

Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors

机译:数据驱动的TP53抑癌基因突变数据库的无偏向策划和超深测序对人类肿瘤的验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cancer mutation databases are expected to play central roles in personalized medicine by providing targets for drug development and biomarkers to tailor treatments to each patient. The accuracy of reported mutations is a critical issue that is commonly overlooked, which leads to mutation databases that include a sizable number of spurious mutations, either sequencing errors or passenger mutations. Here we report an analysis of the latest version of the TP53 mutation database, including 34,453 mutations. By using several data-driven methods on multiple independent quality criteria, we obtained a quality score for each report contributing to the database. This score can now be used to filter for high-confidence mutations and reports within the database. Sequencing the entire TP53 gene from various types of cancer using next-generation sequencing with ultradeep coverage validated our approach for curation. In summary, 9.7% of all collected studies, mostly comprising numerous tumors with multiple infrequent TP53 mutations, should be excluded when analyzing TP53 mutations. Thus, by combining statistical and experimental analyses, we provide a curated mutation database for TP53 mutations and a framework for mutation database analysis.
机译:通过为药物开发和生物标记物提供针对每个患者的治疗方法,癌症突变数据库有望在个性化医学中发挥中心作用。报告的突变的准确性是一个通常被忽视的关键问题,这导致突变数据库包括大量的伪突变,包括测序错误或过客突变。在这里,我们报告了对TP53突变数据库的最新版本的分析,包括34,453个突变。通过在多个独立的质量标准上使用几种数据驱动的方法,我们为贡献给数据库的每个报告获得了质量得分。该分数现在可以用于过滤数据库中的高可信度突变和报告。使用具有超深覆盖率的下一代测序对来自各种类型癌症的整个TP53基因进行测序,验证了我们的治愈方法。总而言之,在分析TP53突变时,应排除所有收集的研究的9.7%,其中大多数是由多个不常见的TP53突变的肿瘤组成。因此,通过结合统计和实验分析,我们提供了一个针对TP53突变的精选突变数据库和一个针对突变数据库分析的框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号